Drug Trial Radar · NCT07360275
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Oct 30, 2026
Study completion Dec 20, 2026
Sponsor
- Lead sponsor
- Vincentage Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
Conditions
- Hypertension
Interventions
VCT220 TabletDrug
Administered orally, with or without food.
VCT220 Placebo TabletDrug
Administered orally, with or without food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in office seated systolic blood pressure (SBP) at Week 20Time frame: From baseline to week 20
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Luhe Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.